BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38723900)

  • 1. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease.
    Negi S; Khurana N; Duggal N
    Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
    O'Hara DM; Kalia SK; Kalia LV
    Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
    Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
    Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could α-synuclein amyloid-like aggregates trigger a prionic neuronal invasion?
    Busquets MA; Espargaró A; Estelrich J; Sabate R
    Biomed Res Int; 2015; 2015():172018. PubMed ID: 25866763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.
    Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?
    Dunning CJ; George S; Brundin P
    Prion; 2013; 7(1):92-7. PubMed ID: 23360753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease from the gut.
    Liddle RA
    Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis.
    Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK
    J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of alpha-synuclein aggregation by dopamine: a review.
    Leong SL; Cappai R; Barnham KJ; Pham CL
    Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.
    Luk KC; Song C; O'Brien P; Stieber A; Branch JR; Brunden KR; Trojanowski JQ; Lee VM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20051-6. PubMed ID: 19892735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.